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Abstract 
Background. Prescription drug misuse among young adults is
increasingly viewed as a public health concern, yet most research has
focused on student populations and excluded high-risk groups.
Furthermore, research on populations who report recent prescription
drug misuse is limited. This study examined patterns of prescription
drug misuse among high-risk young adults in Los Angeles (LA) and
New York (NY), which represent different local markets for illicit and
prescription drugs. 
Design and Methods. Between 2009 and 2011, 596 young adults (16
to 25 years old) who had misused prescription drugs within the past 90
days were interviewed in Los Angeles and New York. Sampling was
stratified to enroll three groups of high-risk young adults: injection
drug users (IDUs); homeless persons; and polydrug users. 
Results. In both sites, lifetime history of receiving a prescription for
an opioid, tranquilizer, or stimulant was high and commonly preceded
misuse. Moreover, initiation of opioids occurred before heroin and ini-
tiation of prescription stimulants happened prior to illicit stimulants.
NY participants more frequently misused oxycodone, heroin, and
cocaine, and LA participants more frequently misused codeine, mari-
juana, and methamphetamine. Combining prescription and illicit
drugs during drug using events was commonly reported in both sites.
Opioids and tranquilizers were used as substitutes for other drugs,
e.g., heroin, when these drugs were not available. 
Conclusion. Patterns of drug use among high-risk young adults
in Los Angeles and New York appear to be linked to differences in
local markets in each city for illicit drugs and diverted prescription
drugs.
Introduction
Prescription drugs have become established as primary substances
of abuse alongside illicit drugs among young adults in the US over the
past 10 years.1 Prescription opioids are the second most commonly
misused drug after marijuana among persons aged 16 to 25 years old
followed by cocaine, prescription tranquilizers, ecstasy, and prescrip-
tion stimulants.2 Prescription drug misuse among young adults is
increasingly viewed as a public health concern since it is associated
with risk practices, such as sexual risk behaviors,3 polydrug use,4 and
injection drug use,5 and negative health outcomes, such as drug
dependence and drug overdose.2
Most research on prescription drug misuse among young adults in
the US has focused exclusively on student populations6-8 or utilized
data from national sentinel surveys.9,10 In all of these studies of young
adults, lifetime prevalence of the most commonly misused prescription
drug – opioids – is no greater than 20% while current misuse (30- or
90-day) is below 5%. While documenting important trends among life-
time misusers, these studies present limited data on young adults who
are current misusers of prescription drugs – the population at the
greatest risk for negative health outcomes.
Additionally, only a few studies have targeted or included high-risk
groups of young adults, such as homeless persons, injection drug
users, or polydrug users, into research examining prescription drug
misuse.11-14 While originally focused on ecstasy or ketamine users,
these studies report much higher rates of prescription drug misuse,
e.g., lifetime opioid misuse exceeding 80%, than studies targeting
young adults who are housed, employed, or in school. Ultimately, stud-
ies that do not include high-risk groups may limit understanding of
more complex patterns of prescription drug misuse. 
Large metropolitan areas are primary places to study prescription
misuse among diverse populations of young adults since current rates
of drug use are highest in these areas.2 New York (NY) and Los
Angeles (LA), the two largest metropolitan areas in the US15 with dis-
tinctly different cultural histories, local economies, and geographies,
each represent particular local drug markets for both illicit and pre-
scription drugs. A picture of each local drug market can be ascertained
by comparing the most prevalent drugs (out of 100%) recently seized
and analyzed by law enforcement in LA and NY, respectively: marijua-
na (38% vs 31%); cocaine (23.6% vs 38.9%); methamphetamine
(16.1% vs 0.5%); heroin (5% vs 10.9%); hydrocodone (1.6% vs 0.7%);
oxycodone (0.4% vs 3.5%); and alprozolam (0.7% vs 2.6%).16
Furthermore, local heroin markets differ in these cities: Mexican tar
heroin predominates in LA, a less pure form compared to South
American powder heroin in NY.17
Significance for public health
Prescription drug misuse among young adults is increasingly viewed as a
public health concern in the US, since it is associated with various risk prac-
tices. Research examining prescription drug misuse among high-risk groups
of young adults is limited. Large metropolitan areas, such as Los Angeles
(LA) and New York (NY), are primary places to study prescription misuse.
Study findings suggest that prescription drugs commonly seized in NY and
LA are those most commonly misused in each city, and that variability in
local markets of diverted drugs may impact frequency of misuse and modes
of administration. Results on ages of initiation suggest that prescription
drugs may serve as pathways to illicit drugs in some cases. Findings on drug
substitution, drug combinations, and polydrug use indicate that prescription
drugs in both NY and LA were frequently consumed as a part of a repertoire
of misuse involving prescription drugs and illicit drugs. 
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In this analysis, we have two primary objectives. First, we aim to
describe overall differences in lifetime and recent patterns of drug use
among young adults in NY and LA who report recent misuse of prescrip-
tion drugs. Based upon differences in local drug markets, we hypothe-
size that NY participants will report greater misuse of oxycodone prod-
ucts, such as Percocet and OxyContin, as well as alprozolam (Xanax),
than LA, while LA participants will report greater misuse of
hydrocodone products, such as Vicodin, than NY. Additionally, we
hypothesize that NY participants will report greater use of cocaine and
heroin than LA while LA participants will report greater use of metham-
phetamine and marijuana than NY. Second, we aim to describe the
interrelationship among prescription and illicit drug misuse among a
sample of high-risk young adults, regarding ages of initiation, patterns
of polydrug use, and modes administration. We hypothesize that pat-
terns of opioid misuse, for instance, will be associated with patterns of
heroin use.
Materials and MethodsSampling 
The analysis is based upon a sample of 596 young adults interviewed
in LA and NY between October 2009 and March 2011. Eligible partici-
pants were between 16 and 25 years old and had engaged in misuse of
a prescription drug, i.e., opioid, tranquilizer, or stimulant, or any com-
bination at least three times in the last 90 days. Misuse was defined as
taking a prescription drug when they were not prescribed for you or that
you took only for the experience or feeling it caused.2,18 Sampling was
stratified to enroll three groups of high-risk young adults with different
access to prescription drugs: injection drug users (IDUs), homeless
persons, and polydrug users. IDUs were defined as injecting a drug
within the past 90 days. Homeless persons were defined as not having
a consistent residence within the past 90 days and/or sleeping on the
street, in a park, or squat; injecting drugs in the past 90 days was an
exclusion criteria for this group. Polydrug users were defined as hav-
ing used two or more drugs (alcohol, illicit, and/or prescriptions) simul-
taneously within the past 90 days; being homeless or injecting drugs in
the past 90 days were exclusion criteria for this group. 
Participants were located using a combination of sampling strate-
gies and data sources. Interviewers employed both targeted19 and
chain-referral sampling20 in combination with recruitment data from
earlier project phases5 to recruit young adults in natural settings, such
as parks, streets, and neighborhoods. In New York, some participants
were recruited from organizations serving homeless youth since home-
less individuals meeting the enrollment criteria were more difficult to
locate in natural settings. A brief screening tool was used to determine
eligibility, and screened individuals received a $3 gift card. Participants
who qualified and were interviewed received a $25 cash incentive. The
study protocol was approved by institutional review boards at Drexel
University, Children’s Hospital Los Angeles, and National Development
and Research Institutes, Inc.
Across the two sites, a total of 4432 individuals were screened and
831 (18.8%) met the enrollment criteria. Among the 831 eligible young
adults, 618 (74.4%) agreed to participate and were interviewed.
Twenty-two participants (3.6%) were later excluded after it was
revealed that they had not misused a prescription drug at least three
times in the last 90 days, resulting in a final sample of 596. Based upon
the stratification criteria, the final sample was comprised of 202 IDUs
(LA=100, NY=102), 192 homeless (LA=102, NY=90) and 202 polydrug
users (LA=101, NY=101). In the final sample, the total number of cur-
rently homeless young adults was 355 since many in the IDU group
were both IDUs and homeless. 
Data collection
The study instrument was developed using Entryware software
(Techneos Systems, Inc., Vancouver, Canada) and loaded onto laptop
computers. The instrument was administered during face-to-face inter-
views with eligible participants by one of two interviewers at each site.
Participants were provided with cards containing response options to
facilitate standardization on some interview questions. Interviews
were conducted in private offices or natural settings, such as fast food
restaurants and parks. Interview data were recorded on laptop comput-
ers and with digital recorders.Measures
The instrument incorporated questions from standardized meas-
ures, previous studies,14 and from topics that emerged during the form-
ative qualitative phase.5 Demographic indicators, such as age, gender,
and race, were assessed using conventional questions. The particular
questions assessing drug use are detailed in Table 1.Data analysis
Statistical analyses were conducted on cross-sectional data using
SPSS version 18. Descriptive statistics were calculated overall and
within site (LA and NY). In most cases, t-tests for continuous variables
and Pearson’s χ2-tests for binary variables compared differences
between sites. In some cases, paired statistical tests, e.g., paired t-tests
and McNemar tests, compared within-site means or frequencies. 
Due to the large number of comparisons, all P-values have been
adjusted using the false discovery rate controlling procedure described
by Benjamini and Hochberg.21,22 The procedure involved ordering the
nominal P-values associated with the entire set of comparisons, com-
puting a Bonferroni-type adjusted critical value based on the ordered
position of the test, and comparing the nominal p-value to the adjusted
critical value. Using this procedure, 11 comparisons previously consid-
ered to be significant at P<0.05 were excluded after adjustment for
multiple comparisons. Adjusted significance levels are presented in the
text and in Tables 2-6.
ResultsDemographics
Sociodemographic variables are summarized in Table 2. Sample par-
ticipants were typically in their early 20s, white, male, and heterosexu-
al. Over half reported being raised in a middle or upper class family.
Most were currently homeless, unemployed, or had been arrested,
while nearly half had health insurance or a history of drug treatment.
About one-third were students. NY participants were more frequently
female (38% vs 26%, P<0.01), white (64% vs 49%, P<0.001), employed
(27% vs 16%, P<0.01) and had health insurance (58% vs 37%, P<0.001)
than LA. Lifetime misuse, prescribed use, and agesof initiation–prescription and illicit drugs
Frequencies of lifetime misuse, prescribed use, and ages of initia-
tion for prescription and illicit drugs are presented in Table 3, includ-
ing a select set of illicit drugs that also may function as pain medica-
tions, tranquilizers, or stimulants. Among prescription drugs, opioids
were the most frequently misused and prescribed. Regarding ages of
prescribed use, stimulants were prescribed at the earliest age, followed
by opioids and tranquilizers. Regarding ages of initiation into misuse,
marijuana was initiated at the earliest age followed by opioids, stimu-
lants, and tranquilizers.
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Table 1. Primary questions from survey instrument used to assess substance use and misuse in the statistical analysis.
Key constructs Question
Lifetime history of receiving a prescription medication Were you ever prescribed the following [pain pills, tranquilizers, stimulants] by a doctor for any
past injury or health condition?
Age of being prescribed a medication How old were you when you were first prescribed these medications?
Lifetime history of prescription drug misuse Have you ever, even once, used any of the following [pain pills, tranquilizers, stimulants] when they
were not prescribed for you or that you took only for the experience or feeling it caused? 
Pain pill list: Vicodin, OxyContin, Percocet, etc. 
Tranquilizer list: Xanax, Klonopin, Valium, etc. 
Stimulant list: Adderall, Ritalin, Concerta, etc.
Age of misuse initiation of prescription drug How old were you the first time you used [pain pills, tranquilizers, stimulants] only for the
experience or feeling they caused?
Lifetime history of misusing prescription drugs via Have you ever [sniffed, smoked, injected] a [pain pill, tranquilizer, stimulant]?
other modes of administration
Polydrug use with prescription drugs Which statement best describes how you’ve taken [pain pills, tranquilizers, stimulants] during the
past 12 months: 1. By itself, without using any other substances before, during, or after; 2.
In combination with one or more substances before, during or after. 
Drug substitution with prescription drugs Have you ever used a [pain pill, tranquilizer, stimulant] as a substitute for another drug that you
wanted, but could not find? If yes, which drugs?
and 
Have you ever used another drug as a substitute for a [pain pill, tranquilizer, stimulant] that you
wanted, but could not find? If yes, which drugs?
Recent prescription drug misuse How long has it been since you last used any [pain pills, tranquilizers, stimulants] that were not
prescribed for you or that you took only for the experience or feeling it caused?
Lifetime history of using illicit drugs Have you ever used [illicit drug list]? 
List of illicit drugs: marijuana, LSD, ecstasy, heroin, cocaine, crack, crystal meth, ketamine. 
Age of initiation of illicit drugs How old were you the first time you used [illicit drug list]?
Lifetime history of injecting illicit drugs Have you ever injected any of the following [illicit drug list]?
Recent illicit drug misuse How long has it been since you last used [illicit drug list]?
Lifetime history of receiving a prescription medication Were you ever prescribed the following [pain pills, tranquilizers, stimulants] by a doctor for any
past injury or health condition?
Age of being prescribed a medication How old were you when you were first prescribed these medications?
Lifetime history of prescription drug misuse Have you ever, even once, used any of the following [pain pills, tranquilizers, stimulants] when they
were not prescribed for you or that you took only for the experience or feeling it caused? 
Pain pill list: Vicodin, OxyContin, Percocet, etc. 
Tranquilizer list: Xanax, Klonopin, Valium, etc. 
Stimulant list: Adderall, Ritalin, Concerta, etc.
Age of misuse initiation of prescription drug How old were you the first time you used [pain pills, tranquilizers, stimulants] only for the
experience or feeling they caused?
Lifetime history of misusing prescription Have you ever [sniffed, smoked, injected] a [pain pill, tranquilizer, stimulant]?
drugs via other modes of administration
Polydrug use with prescription drugs Which statement best describes how you've taken [pain pills, tranquilizers, stimulants] during the
past 12 months: 
1. By itself, without using any other substances before, during, or after; 
2. In combination with one or more substances before, during or after.
Drug substitution with prescription drugs Have you ever used a [pain pill, tranquilizer, stimulant] as a substitute for another drug that you
wanted, but could not find? If yes, which drugs?
and 
Have you ever used another drug as a substitute for a [pain pill, tranquilizer, stimulant] that you
wanted, but could not find? If yes, which drugs?
Recent prescription drug misuse How long has it been since you last used any [pain pills, tranquilizers, stimulants] that were not
prescribed for you or that you took only for the experience or feeling it caused?
Lifetime history of using illicit drugs Have you ever used [illicit drug list]? 
List of illicit drugs: marijuana, LSD, ecstasy, heroin, cocaine, crack, crystal meth, ketamine. 
Age of initiation of illicit drugs How old were you the first time you used [illicit drug list]?
Lifetime history of injecting illicit drugs Have you ever injected any of the following [illicit drug list]?
Recent illicit drug misuse How long has it been since you last used [illicit drug list]?
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Nearly all of the significant between-site differences pertain to pre-
scription or illicit stimulants. A significantly greater percentage of LA par-
ticipants had been prescribed stimulants compared to NY (51% vs 39%,
P<0.05). Moreover, LA participants were prescribed stimulants at signifi-
cantly earlier ages than NY (10.9 vs 12.2 years, P<0.05) and initiated
stimulant misuse at significantly earlier ages than NY (15.4 vs 16.2 years,
P<0.05). However, a significantly greater percentage of NY participants
reported lifetime misuse of prescription stimulants than LA (84% vs 71%,
P<0.001). The only significant illicit drug site difference pertained to
methamphetamine: a significantly greater percentage of LA participants
used methamphetamine compared to NY (61% vs 38%, P<0.001).
Regarding within site differences (all results and paired t-tests not
shown in Table 3), participants in NY and LA were prescribed stimu-
lants at significantly earlier ages than their first misuse of stimulants
(12.4 vs 15.4 years; paired t(102)= -6.68, P<0.001; 11.0 vs 14.7 years;
paired t(125)= -9.36, P<0.001, respectively). Moreover, participants in
both NY and LA initiated misuse of prescription stimulants at signifi-
cantly earlier ages than cocaine, methamphetamine, and ecstasy (16.1
vs 17.1 years; paired t(209)= -5.95, P<0.001; 15.2 vs 16.9 years; paired
t(190)= -7.63 P<0.001, respectively). Among those prescribed opioids,
no significant differences emerged between age of prescribed use and
age of first misuse. In both NY and LA, participants initiated misuse of
opioids at significantly earlier ages than heroin (14.8 vs 17.5 years;
paired t(149)= -13.52, P<0.001; 14.6 vs 17.5 years; paired t(137)= -
11.43, P<0.001, respectively).Specific prescription drugs misused
Frequencies of lifetime misuse of specific types of prescription
drugs, which may provide insights into local prescribing practices and
drug diversion, are presented in Table 4. Participants reported lifetime
misuse of a wide range of prescription opioids of differing potencies.*
The most frequently misused opioids included hydrocodone, oxy-
codone, and codeine. A significantly greater percentage of NY partici-
pants reported misuse of any oxycodone product compared to LA (89%
vs 71%, P<0.001), whereas a significantly greater percentage of LA par-
ticipants reported misuse of codeine compared to NY (62% vs 51%,
P<0.05). Vicodin was the most frequently misused formulation of
hydrocodone, and OxyContin was the most frequently misused formu-
lation of oxycodone. Except for Percodan, NY participants reported sig-
nificantly more misuse of all formulations and combinations of oxy-
codone than LA, e.g., Percocet (73% vs 40%, P<0.001). Within sites, LA
participants reported significantly more misuse of any hydrocodone
than any oxycodone (87% vs 71%; McNemar χ2(1)= 22.0, P<0.001).
Misuse of any opioid substitution medications, such as methadone or
buprenorphine, was reported by less than half of all participants, while
NY participants reported significantly more misuse of Suboxone (34%
vs 17%, P<0.001) and Subutex (14% vs 6%, P<0.01) than LA.
Xanax was the most frequently misused tranquilizer, followed by
Valium and Klonopin. NY participants reported significantly more mis-
use of Klonopin (60% vs 41%, P<0.001), while LA participants reported
significantly more misuse of Seroquel (50% vs 38%, P<0.05). Adderall
was the most frequently misused stimulant followed by Ritalin,
Concerta, and Dexedrine. NY participants reported significantly more
misuse of Adderall (75% vs 60%, P<0.001), Ritalin (51% vs 41%,
P<0.05), and Concerta (23% vs 15%, P<0.05) than LA.
*There are notable differences in the potencies of prescription opioids. For instance, oxy-
codone is seven to twelve times stronger than codeine, while hydrocodone is two to eight
times stronger than codeine assuming similar modes of administration.23
[Journal of Public Health Research 2012; 1:e6] [page 25]
Article
Table 2. Demographics by site (Los Angeles and New York). 
Demographic factors LA, n=303 (%) NY, n=293 (%) Total, n=596, (%) χ2-test
Age (mean ± SD) 20.91 (2.11) 20.81 (2.00) 20.86 (2.06) ns
Gender° χ2(1)= 9.4**
Male 213 (70) 177 (61) 390 (66)
Female 78 (26) 112 (38) 190 (32)
Transgender 12 (4) 3 (1) 15 (2)
Race# χ2(1)=14.0***
Non-Hispanic White 147 (49) 186 (64) 333 (56)
Nonwhite: 155 (51) 105 (36) 260 (44)
Hispanic 52 (17) 34 (12) 86 (15)
Multiracial 45 (15) 46 (16) 91 (15)
Black/African American 46 (15) 19 (7) 65 (11)
Asian/Pacific Islander 7 (2) 4 (1) 11 (2)
Native American 5 (2) 2 (0.7) 7 (1)
Sexual identity ns
Heterosexual 210 (70) 183 (63) 393 (66)
LGBT 93 (31) 108 (37) 201 (34)
Socioeconomic status growing up ns
Poor or lower class 140 (47) 124 (43) 264 (45)
Middle or upper class 161 (54) 167 (57) 328 (55)
Completed high school/GED 222 (73) 223 (76) 445 (75) ns
Currently in school 97 (32) 100 (34) 197 (33) ns
Currently employed 49 (16) 79 (27) 128 (22) χ2(1)=10.3**
Currently insured 111 (37) 169 (58) 280 (47) χ2(1)=28.6***
Currently homeless 194 (64) 161 (55) 355 (60) ns
History of arrest 241 (80) 213 (73) 454 (76) ns
History of jail time 203 (67) 182 (62) 385 (65) ns
Drug treatment 123 (41) 127 (43) 250 (42) ns
°χ2-test based on male vs female only; #χ2-test based on white vs nonwhite only; LGBT, lesbian, gay, bisexual, or transgender; ns, non-significant; *P<0.05; **P<0.01; ***P<0.001.
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Prescription drug using practices and risk behaviors
Frequencies of lifetime modes of administering specific categories
of prescription drugs and illicit drugs are presented in Table 5.
Participants administered prescription drugs via a range of modalities
other than swallowing: snorting was more commonly reported than
either injecting or smoking. Opioids were more frequently sniffed,
smoked, and injected than either stimulants or tranquilizers. NY partic-
ipants were significantly more likely to sniff opioids (68% vs 53%,
P<0.001) and stimulants (58% vs 43%, P<0.01) than LA. LA partici-
pants more commonly smoked all three types of drugs compared to NY
participants, but only opioids exhibited a significant difference (27% vs
14%, P<0.001). No site differences regarding injecting prescription
drugs were observed; overall, approximately one-quarter of participants
ever injected a prescription opioid.
Comparing histories of injecting illicit drugs revealed more site dif-
ferences. NY participants reported significantly greater frequency of
injecting heroin (41% vs 30%, P<0.05), cocaine (32% vs 17%, P<0.001),
and crack (16% vs 9%, P<0.05), while LA participants reported signifi-
cantly greater frequency of injecting methamphetamine (27% vs 12%,
P<0.001). Comparing injecting heroin and opioids within sites, NY par-
ticipants reported significantly greater frequency of injecting heroin
than opioids (41% vs 29%, P<0.01), whereas no significant differences
in LA were observed.
Polydrug use, or combining drugs during a drug-using event, was a
common feature of prescription drug misuse: a majority of misusers of
both opioids and tranquilizers reported that combining these drugs
with other drugs was typical in the past 12 months. No site differences
were observed. Substituting with prescription drugs, e.g., prescription
opioids, when other drugs, e.g., heroin, could not be located was com-
monly reported: half of the sample’s opioid users reported using an opi-
oid as a substitute, though fewer tranquilizer and stimulant users
reported this practice. No site differences were found. Substituting
with other drugs when prescription drugs could not be found was less
frequently reported. However, among those that did, LA participants
reported significantly greater frequency of using another drug as a sub-
stitute for opioids (36% vs 27%, P<0.05), tranquilizers (28% vs 19%,
P<0.05), and stimulants (22% vs 13%, P<0.05) than NY participants.Current misuse of prescription and illicit drugs
Frequencies of 90-day misuse of prescription and illicit drugs are
presented in Table 6. All participants misused at least one prescription
drug within the past 90-days (an enrollment criterion for the study).
Opioids and tranquilizers were the most frequently misused, followed
by stimulants. No significant differences were found by site.
Participants also reported frequent use of illicit drugs in the past 90
days. As predicted, NY participants reported significantly greater use of
heroin (40% vs 29%, P<0.01) and cocaine (59% vs 36%, P<0.001),
while LA participants reported significantly greater use of marijuana
(97% vs 90%, P<0.001) and methamphetamine (40% vs 12%, P<0.001).
Participants reported co-occurring misuse of prescription and illicit
Lankenau et al.
Table 3. Lifetime misuse/use of prescription/illicit drugs, drugs prescribed, and age of initiation by site (Los Angeles and New York).
Lifetime misuse/use LA, n=303 (%) NY, n=293 (%) Total, n=596 (%) χ2-test
Misuse of prescription drugs
Opioids 292 (96) 284 (97) 576 (97) ns
Tranquilizers 266 (88) 267 (91) 533 (89) ns
Stimulants 215 (71) 247 (84) 462 (78) χ2(1)=15.2***
Lifetime misuse of all 3 189 (62) 222 (76) 411 (69) χ2(1)=12.5**
Drugs prescribed
Opioids 232 (77) 202 (69) 434 (73) ns
Tranquilizers 138 (46) 133 (45) 271 (46) ns
Stimulants 154 (51) 115 (39) 269 (45) χ2(1)=8.1*
Any of 3 274 (90) 248 (85) 522 (88) ns
Use of illicit drugs
Marijuana 302 (100) 292 (99) 593 (100) ns
Ecstasy 257 (85) 245 (84) 502 (84) ns
Cocaine 244 (81) 256 (87) 500 (84) ns
Methamphetamine 186 (61) 111 (38) 297 (50) χ2(1)=32.9***
Heroin 140 (46) 152 (52) 292 (49) ns
Crack 132 (44) 118 (40) 250 (42) ns
Age of initiation LA (mean, SD) NY (mean, SD) Total (mean, SD) t-test
t(df), P-value
Misuse of prescription drugs
Stimulants 15.4 (3.5) 16.2 (2.5) 15.8 (3.1) t(460)= -2.7*
Opioids 15.6 (3.1) 15.5 (2.4) 15.5 (2.8) ns
Tranquilizers 16.3 (3.0) 16.3 (2.7) 16.3 (2.9) ns
First prescribed
Stimulants 10.9 (4.4) 12.2 (4.6) 11.5 (4.5) t(267)= -2.4*
Opioids 15.4 (3.9) 15.4 (3.8) 15.4 (3.8) ns
Tranquilizers 16.0 (3.6) 16.2 (3.2) 16.1 (3.4) ns
Use of illicit drugs
Marijuana 13.3 (3.1) 13.6 (2.4) 13.4 (2.8) ns
Cocaine 16.7 (2.6) 16.6 (2.3) 16.6 (2.4) ns
Methamphetamine 16.9 (3.3) 17.3 (2.6) 17.1 (3.0) ns
Ecstasy 17.2 (2.6) 17.2 (2.1) 17.2 (2.4) ns
Heroin 17.5 (2.6) 17.5 (2.3) 17.5 (2.4) ns
Crack 17.4 (2.6) 17.9 (2.4) 17.6 (2.5) ns
ns, non-significant; *P<0.05; **P<0.01; ***P<0.001. 
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drugs within the past 90 days, which may indicate patterns of polydrug
use or drug substitution. The co-occurrence of opioids and tranquiliz-
ers was most frequent. No significant differences by site were found.
Regarding illicit drugs, the three most frequently reported co-occur-
rences were tranquilizers and cocaine, opioids and heroin, and tran-
quilizers and ecstasy. While multiple significant site differences were
found, the largest differences involved LA participants reporting more
frequent combinations of tranquilizers and methamphetamine (33% vs
9%, P<0.001) and NY participants reporting more frequent combina-
tions of tranquilizers and cocaine (47% vs 29%, P<0.001). Additionally,
NY participants reported more frequent combinations of stimulants
and cocaine (32% vs 19%, P<0.01).
Discussion
This is the first study to our knowledge that compares patterns of
prescription and illicit drug misuse in two large urban areas among
diverse samples of young adults who are current misusers of prescrip-
tion drugs. Lifetime misuse of particular prescription drugs and recent
use of illicit drugs closely tracked drug seizure data and largely con-
firmed our first hypotheses: more frequent misuse of oxycodone, hero-
in, and cocaine in NY, and more frequent use of marijuana and
methamphetamine in LA.16 Hydrocodone was more frequently misused
than oxycodone in LA, which is also consistent with monitoring data.16
These findings suggest that prescription drugs commonly seized in NY
and LA are in fact those most commonly misused in each city, and that
variability in local markets of diverted drugs may impact frequency of
misuse. 
Moreover, variations in local drug markets may be factors in explain-
ing differences in modes of administrating opioids and heroin in each
city. For instance, Mexican heroin found in LA is frequently in tar form,
whereas Colombian heroin found in NY is commonly in powder form.24
In NY, where sniffing powder heroin is common,25 NY participants
more frequently sniffed opioids than LA participants. In LA, where
smoking tar heroin is common,26 LA participants more frequently
smoked opioids than NY participants. These results suggest that partic-
ipants may have transferred local practices for administering different
forms of heroin in each site, i.e., sniffing and smoking, towards admin-
istering prescription opioids. These findings provide support for our
second hypothesis which proposed an interrelationship between opioid
and heroin use.
Furthermore, our results suggest the differences in heroin markets
– both supply and form – did not impact lifetime frequency of injecting
prescription opioids. NY participants reported more frequent lifetime
heroin use, 90-day use, and heroin injection than LA. However, no dif-
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Table 4. Specific prescription drug type misused by site (Los Angeles and New York).
Type of prescription drug LA, n=303 (%) NY, n=293 (%) Total, n=596, (%) χ2-test
Opioids
Any hydrocodone 263 (87) 246 (84) 509 (85) ns
Vicodin (hydrocodone) 257 (85) 234 (80) 491 (82) ns
Lortab (hydrocodone) 89 (29) 83 (28) 172 (29) ns
Norco (hydrocodone) 31 (10) 28 (10) 59 (10) ns
2 or more hydrocodones 93 (31) 85 (29) 178 (30) ns
Any oxycodone 216 (71) 261 (89) 477 (80) χ2(1)=29.5***
Oxycontin (oxycodone) 196 (65) 220 (75) 416 (70) χ2(1)=7.6*
Percocet (oxycodone) 120 (40) 215 (73) 335 (56) χ2(1)=69.0***
Percodan (oxycodone) 41 (14) 44 (15) 85 (14) ns
Roxicet (oxycodone) 32 (11) 60 (21) 92 (15) χ2(1)=11.2**
2 or more oxycodones 114 (38) 183 (63) 297 (50) χ2(1)=36.7***
Any opioid therapy 121 (40) 131 (45) 252 (42) ns
Methadone 106 (35) 103 (35) 209 (35) ns
Suboxone (buprenorphine/naloxone) 51 (17) 101 (34) 152 (25) χ2(1)=24.4***
Subutex (buprenorphine) 19 (6) 41(14) 60 (10) χ2(1)=9.8**
2 or more opioid therapy 40 (13) 78 (26) 118 (20) χ2(1)=16.9***
Codeine 188 (62) 150 (51) 338 (57) χ2(1)=7.1*
Morphine 144 (48) 125 (43) 269 (45) ns
Dilaudid (hydromorphone) 61 (20) 67 (23) 128 (22) ns
Fentanyl 47 (16) 73 (25) 120 (20) χ2(1)=8.2*
Demerol (meperidine) 57 (19) 41 (14) 98 (16) ns
Other 44 (15) 48 (16) 92 (15) ns
Tranquilizers
Xanax (alprozolam) 222 (73) 234 (80) 456 (77) ns
Valium (diazepam) 157 (52) 169 (58) 326 (55) ns
Klonopin (clonazepam) 124 (41) 177 (60) 301 (51) χ2(1)=23.1***
Seroquel (quetiapine) 150 (50) 110 (38) 260 (44) χ2(1)=8.5*
Ativan (lorazepam) 58 (19) 71 (24) 129 (22) ns
Other 63 (21) 73 (25) 136 (23) ns
Stimulants
Adderall (amphetamine and dextroamphetamine) 183 (60) 220 (75) 403 (68) χ2(1)=15.2***
Ritalin (methylphenidate) 123 (41) 148 (51) 271 (46) χ2(1)=6.1*
Concerta (methylphenidate) 45 (15) 67 (23) 112 (19) χ2(1)=6.4*
Dexedrine (dextroamphetamine) 34 (11) 52 (18) 86 (14) ns
Other 25 (8) 35 (12) 60 (10) ns
ns, non-significant; *P<0.05; **P<0.01; ***P<0.001. 
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Table 5. Lifetime illicit and prescription drug misuse practices by site (Los Angeles and New York). 
Drug using practices LA, n=303 (%) NY, n=293 (%) Total, n=596 (%) χ2-test
Ever sniff Rx drugs°
Any 204 (67) 237 (81) 441 (74) χ2(1)=15.6***
Opioids 159 (53) 198 (68) 357 (60) χ2(1)=14.1***
Tranquilizers 130 (43) 140 (48) 270 (45) ns
Stimulants 131 (43) 169 (58) 300 (50) χ2(1)=12.4**
Ever smoke Rx drugs#
Any 95 (31) 59 (20) 154 (26) χ2(1)=9.8**
Opioids 82 (27) 41 (14) 123 (21) χ2(1)=15.5***
Tranquilizers 27 (9) 15 (5) 42 (7) ns
Stimulants 19 (6) 14 (5) 33 (6) ns
Ever inject Rx drugs§
Any 77 (25) 84 (29) 161 (27) ns
Opioids 72 (24) 82 (28) 154 (26) ns
Tranquilizers 33 (11) 30 (10) 63 (11) ns
Stimulants 16 (5) 25 (9) 41 (7) ns
Ever inject illicit drugs
Heroin 91 (30) 121 (41) 212 (36) χ2(1)=8.1*
Cocaine 51 (17) 94 (32) 145 (24) χ2(1)=18.6***
Crack 26 (9) 47 (16) 73 (12) χ2(1)=7.6*
Methamphetamine 81 (27) 36 (12) 117 (20) χ2(1)=19.9***
Polydrug use in conjunction with Rx drug
Opioids 191 (71) 201 (78) 392 (74) ns
Tranquilizers 169 (70) 177 (74) 346 (72) ns
Stimulants 79 (53) 106 (61) 185 (57) ns
Ever used Rx as substitute for another drug
Opioids 151 (50) 149 (51) 300 (50) ns
Tranquilizers 104 (34) 112 (38) 216 (36) ns
Stimulants 65 (22) 74 (25) 139 (23) ns
Ever used another drug as substitute for Rx
Opioids 110 (36) 80 (27) 190 (32) χ2(1)=5.6*
Tranquilizers 86 (28) 55 (19) 141 (24) χ2(1)=7.6*
Stimulants 65 (22) 37 (13) 102 (17) χ2(1)=8.2*
°χ2-test based on sniffed any vs none only (but as we discover much of the difference is driven by the opioids); #χ2-test based on smoked any vs none only; §χ2-test based on injected any vs none only; ns, non-signif-
icant; *P<0.05; **P<0.01; ***P<0.001. 
Table 6. 90-day misuse of illicit and prescription drugs by site (Los Angeles and New York.) 
Drug type(s) LA, n=303 (%) NY, n=293 (%) Total, n=596 (%) Difference test
90-day misuse of Rx drugs
Opioids 246 (82) 229 (78) 475 (80) ns
Tranquilizers 213 (71) 209 (71) 422 (71) ns
Stimulants 122 (41) 143 (49) 265 (45) ns
90-day use of illicit drugs
Marijuana 295 (97) 263 (90) 558 (94) χ2(1) =16.0***
Cocaine 109 (36) 174 (59) 283 (47) χ2(1) =32.5***
Ecstasy 130 (43) 106 (36) 236 (40) ns
Heroin 87 (29) 119 (40) 206 (35) χ2(1) =9.4**
Methamphetamine 120 (40) 34 (12) 154 (26) χ2(1) =61.3***
Crack 61 (20) 50 (17) 111 (19) ns
Rx combinations 
Opioids & tranquilizers 175 (58) 167 (57) 342 (57) ns
Opioids & stimulants 85 (28) 100 (34) 185 (31) ns
Tranquilizers & stimulants 90 (30) 97 (33) 187 (31) ns
Rx and illicit combinations 
Opioids & heroin 84 (28) 111 (38) 195 (33) χ2(1) =7.0*
Tranquilizers & heroin 75 (25) 96 (32) 171 (29) ns
Stimulants & cocaine 59 (19) 93 (32) 152 (25) χ2(1) =11.8**
Stimulants & ecstasy 63 (21) 61 (21) 124 (21) ns
Stimulants & methamphetamine 51 (17) 23 (8) 74 (12) χ2(1) =11.1**
Tranquilizers & cocaine 89 (29) 139 (47) 228 (38) χ2(1) =20.6***
Tranquilizers & ecstasy 100 (33) 89 (30) 189 (32) ns
Tranquilizers & methamphetamine 101 (33) 27 (9) 128 (21) χ2(1) =102.9***
ns, non-significant; *P<0.05; **P<0.01; ***P<0.001.
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ferences were found in lifetime history of injecting opioids - about one-
quarter of participants in both sites had injected opioids. In other
words, greater use of heroin in NY- including injection - did not trans-
late into more frequent injection of prescription opioids in NY com-
pared to LA.
While 90-day opioid misuse did not vary between sites, lifetime data
suggest greater misuse and availability of more potent opioids in NY,
such as oxycondone, fentanyl, and buprenorphine, than in LA.
Significantly, the use of more potent prescription opioids in NY coincid-
ed with a more robust heroin market in NY. Previous research indicat-
ed that potent opioids were particularly useful towards self-medicating
for heroin withdrawal as well as functioning as a substitute when hero-
in was unavailable.5 While prior studies report opioid misuse in cities
where heroin is scarce,27,28 these results indicate active misuse of opi-
oids in cities where heroin is frequently available.29 The fact that young
adults accessed both opioids and heroin, for instance, suggests the
potential for overlapping markets for prescription and illicit drugs,
which is in contrast to the conventional view of separate markets.30
Findings on drug substitution, drug combinations, and polydrug use
indicate that prescription drugs in both NY and LA were frequently con-
sumed as a part of a broader repertoire of misuse involving prescription
drugs and illicit drugs.11,14
Opioids and tranquilizers were used as substitutes for other drugs
when these drugs were not available. The most common drug combina-
tions reported in the past 90 days were opioids and tranquilizers,
cocaine and tranquilizers, and heroin and opioids. Qualitative research
among young IDUs suggests that particular drug combinations, such as
opioids and tranquilizers, are frequently used simultaneously or con-
secutively during polydrug using events.5 Significantly, the misuse of
prescription drugs in polydrug combinations presents a greater chance
for both fatal and non-fatal overdose.31,32
Lifetime history of receiving a prescription for an opioid, tranquiliz-
er, or stimulant was high (88%), particularly for opioids (73%).33 In
both sites, participants were prescribed stimulants at significantly ear-
lier ages than the age of first misuse, suggesting that participants used
these drugs as prescribed for an extended period before misusing.34 In
contrast, initiation into misuse of opioids and receiving a prescription
for an opioid occurred at approximately the same age in both sites. In
these cases, several factors may have played a role in initiation, includ-
ing developing a physical dependence on the prescribed drug, enjoying
the novel psychoactive features of the prescribed drug, or inadequate
management of pain.5,35,36 Overall, initiation of prescription drugs
occurred during the early to mid-teens, after marijuana and before
other illicit substances. In particular, initiation of opioids occurred
before heroin and initiation of prescription stimulants happened prior
to illicit stimulants. These findings on ages of initiation, in combina-
tion with the high percentage of participants who used heroin, cocaine,
and methamphetamine, suggest that prescription drugs may serve as
pathways to illicit drugs in some cases.5,37,38
Overall, these results suggest that metropolitan drug seizure data16
may be accurate predictors of the most frequently misused prescription
and illicit drugs among certain subgroups of users in some cities. This
information could be useful for the other 20 cities where this data is
available in confirming that existing programs are targeting the most
commonly misused drugs or developing new types of drug treatment
programs for both prescription and illicit drugs. Future studies should
conduct longitudinal research on young adults in different cities or
regions to examine local drug markets and determine how fluctuations
in local drug markets impact patterns of illicit and prescription drug
misuse, including use of local drug treatment services. Findings could
guide drug treatment providers towards developing programs for future
young adult clients who may present increasingly complex histories of
drug use.
This study has some limitations. First, results are based upon cross-
sectional data. Hence, only associations between variables can be
determined rather than causal relationships. Second, the sample is
comprised of young adults who were currently homeless and/or had
engaged in high-risk behaviors, such as injection drug use or polydrug
use, in NY and LA. Consequently, the results may not generalize to the
larger population of young adults who are housed or who do not engage
in these risk behaviors, or to high-risk young adults in other cities.
Nonetheless, the sample represents an important subgroup of young
adults who should be included in future studies to better describe the
spectrum of prescription drug misuse. 
In conclusion, patterns of prescription drug misuse among high-risk
young adults in LA and NY appear to conform to and be shaped by dif-
ferences in local markets for illicit drugs in each city. Our findings indi-
cate that current misuse of prescription drugs in both cities encom-
passes a broad range of practices, such as sniffing, injecting, polydrug
use, and drug substitution, and involves frequent misuse of illicit sub-
stances. Initiation into prescription drug misuse was often preceded by
being prescribed one or more types of prescription drugs, which was
then followed by initiating illicit drugs with similar psychotropic
effects. Our results suggest that drug treatment providers may antici-
pate increasingly complex patterns of prescription and illicit drug use
among newly enrolled young adult clients. 
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